XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.53

XOMA Co. (NASDAQ:XOMA)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $25.53 and traded as high as $29.25. XOMA shares last traded at $29.04, with a volume of 17,030 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently commented on XOMA shares. HC Wainwright boosted their price objective on XOMA from $74.00 to $117.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

XOMA Trading Down 0.7 %

The company has a market capitalization of $339.77 million, a PE ratio of -7.41 and a beta of 0.92. The company’s fifty day moving average is $26.70 and its 200-day moving average is $25.53. The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71.

Hedge Funds Weigh In On XOMA

A number of institutional investors and hedge funds have recently modified their holdings of XOMA. BNP Paribas Financial Markets lifted its position in shares of XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares in the last quarter. Rhumbline Advisers boosted its holdings in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the period. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in XOMA in the 1st quarter worth $212,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.